Information Provided By:
Fly News Breaks for November 14, 2018
ONCE, BMRN, SGMO
Nov 14, 2018 | 06:49 EDT
JPMorgan analyst Eric Joseph downgraded Sangamo Therapeutics (SGMO) to Neutral from Overweight and lowered his price target for the shares to $11 from $35. Following the company's Q3 results, the analyst has "growing skepticism" about its lead development programs and "their potential for value creation over the foreseeable future." Visibility into the initial efficacy of the SB-525 / Hemophilia A program "continues to elude, now with indefinite timelines," Joseph tells investors in a research note. With relatively slower recruitment to date, the analyst struggles to see how SB-525 closes ground with the two later-stage competitor FVIII gene therapy programs from BioMarin (BMRN) and Spark Therapeutics (ONCE).
News For SGMO;BMRN;ONCE From the Last 2 Days
There are no results for your query SGMO;BMRN;ONCE